Connect with us

Hi, what are you looking for?

Jewish Business News


Mylan receives US FTC Clearance to buy Perrigo

Mylan begins trading on the TASE; agrees to sell rights and assets related to seven generic drugs to secure regulatory approval of its hostile takeover of Perrigo.

(L-R) Robert J Coury,   Mylan and Josegh Papa,   Periggo
Under the settlement agreement with the Federal Trade Commission, subject to final approval, Mylan NV has agreed to sell the rights and assets related to seven generic drugs to secure regulatory approval of its hostile takeover of Perrigo Co.

Mylan is offering $75 in cash and 2.3 shares of Mylan for each Perrigo share. This amounts to about $180 per share on Perrigo’s current market price for a total deal of $26.5 billion. Perrigo opposes the deal and recommends shareholders to follow suit. The offer is scheduled to expire on Nov. 13.

WSJ reports that Mylan targets $800 million in savings a year, but Perrigo, which tried to block the offer, has challenged how Mylan would achieve the savings.

Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at
Thank you.

Mylan is set to sell the seven generics to New Jersey-based Alvogen Group Inc.

Mylan chairman Robert Coury is currently in Israel in attempts to persuade Perrigo shareholders to support his company’s bid. He said is a statement: “We are delighted to have received FTC clearance, making our offer for Perrigo now unconditional other than the one final step, which now rests solely in the hands of Perrigo shareholders. We are very confident that Perrigo shareholders will support this transaction.”

Globes said that Coury range the opening bell on the Tel Aviv Stock Exchange this morning as Mylan’s share price rose 2.6% during its first session on the Israeli capital market. Mylan has dual-listed on the TASE in its efforts to persuade Israeli investors to support its takeover bid.





You May Also Like

World News

In the 15th Nov 2015 edition of Israel’s good news, the highlights include:   ·         A new Israeli treatment brings hope to relapsed leukemia...


The Movie The Professional is what made Natalie Portman a Lolita.


After two decades without a rating system in Israel, at the end of 2012 an international tender for hotel rating was published.  Invited to place bids...

VC, Investments

You may not become a millionaire, but there is a lot to learn from George Soros.